Para-hydroxyphenylacetate, often referred to as P-Hydroxyphenylacetate or PARA, is a diagnostic tool used in functional medicine and clinical assessments. PARA is a key intermediate in the degradation pathway of the amino acid tyrosine and is produced during the breakdown of tyrosine in the body. Elevated levels of PARA on the panel can provide valuable insights into various metabolic and enzymatic processes. An abnormal PARA level can be indicative of issues related to tyrosine metabolism, such as deficiencies in enzymes like phenylalanine hydroxylase or tyrosine aminotransferase. It can also suggest disruptions in gut microbiota, as some bacteria produce PARA as a metabolic byproduct.

Parabens are a class of chemical used as preservatives and have bactericidal and fungicidal properties. Parabens are used in many personal care and beauty products, and pharmaceuticals. Parabens are man-made chemicals often used in small amounts as preservatives in cosmetics, pharmaceuticals, foods, and beverages. Common parabens are methylparaben, ethylparaben, propylparaben, and butylparaben. Often more than one paraben is used in a single product. How People Are Exposed to Parabens: People can be exposed to parabens through touching, swallowing, or eating products that contain parabens. Many products, such as makeup, moisturizers, hair-care products, and shaving creams, contain parabens. Parabens in these products are absorbed through the skin. Parabens also can enter the body when pharmaceuticals, foods, and drinks containing parabens are swallowed or eaten. Parabens that enter the body are quickly excreted. How Parabens Affect People’s Health: Human health effects from environmental exposure to low levels of parabens are unknown. In 2006, the industry-led Cosmetic Ingredient Review (CIR), in a partnership with the U.S. Food and Drug Administration (FDA), determined that there was no need to change CIR’s original conclusion from 1984 that parabens are safe for use in cosmetics. The FDA allows single or multiple parabens to be added to food or food packaging as antimicrobials to prevent food spoilage. Levels of Parabens in the U.S. Population: Centers for Disease Control and Prevention scientists measured parabens in the urine of more than 2,548 participants aged six years and older who took part in the National Health and Nutrition Examination Survey (NHANES) during 2005–2006. By measuring these chemicals in urine, scientists can estimate the amount of parabens that has entered people’s bodies. CDC scientists found Methylparaben and propylparaben in the urine of most of the people tested, indicating widespread exposure to these parabens in the U.S. population. In adults younger than age 60, non-Hispanic blacks had higher levels of methyl paraben than non-Hispanic whites. Females had several-fold higher concentrations of methylparaben and propylparabens than males, which likely reflect the greater use of products containing parabens. Finding a measurable amount of parabens in urine does not imply that they cause an adverse health effect. Biomonitoring studies on levels of parabens provide physicians and public health officials with reference values so that they can determine whether people have been exposed to higher levels of parabens than are found in the general population. Biomonitoring data can also help scientists plan and conduct research on exposure and health effects. References: Chen J, et al. Antiandrogenic properties of parabens and other phenolic containing small molecules in personal care products. Toxicol Applied Pharmacol, 2007; 221:278–284. Oishi, S. Effects of propyl paraben on the male reproductive system. Food Chem Toxicol, 2002; 40:1807–1813. Referenced links: https://www.cdc.gov/biomonitoring/parabens_factsheet.html

Paraneoplastic Antibodies (Paraneoplastic Ab) Paraneoplastic antibodies are autoantibodies produced by the immune system in response to a tumor elsewhere in the body. Instead of targeting the tumor directly, these antibodies mistakenly attack the nervous system, leading to a group of disorders known as Paraneoplastic Neurologic Syndromes (PNS). These antibodies are important biomarkers that can help detect hidden (occult) cancers and explain unexplained neurological symptoms. Clinical Relevance: The presence of paraneoplastic antibodies may indicate an autoimmune neurological condition triggered by an underlying malignancy. These markers can assist in diagnosing neurological symptoms such as: Encephalopathy Seizures Myelopathy Sensory neuropathy Cerebellar degeneration Stiff-person syndrome Commonly Tested Antibodies Include: Anti-Hu (ANNA-1) – linked to small cell lung cancer Anti-Yo (PCA-1) – associated with breast and gynecologic cancers Anti-Ri (ANNA-2) – seen in breast and lung cancer CRMP-5 (CV2), Ma2, Amphiphysin, and others Interpretation Notes: A positive result supports a potential diagnosis of PNS and may suggest an underlying cancer, prompting further diagnostic imaging and oncology evaluation. A negative result does not rule out all clinically relevant antibodies. If symptoms persist, phenotype-specific antibody panels (e.g., for encephalopathy, dementia, or neuropathy) should be considered. Why It Matters: Early detection of paraneoplastic antibodies can lead to earlier diagnosis and treatment of cancer and may prevent or reduce irreversible neurological damage.